

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586


Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31st DECEMBER, 2016

Rs. In Lakhs

Sr. No.	Particulars	Unaudited					Audited
		3 months ended 31/12/2016	Preceding 3 months ended 30/09/2016	Corresponding 3 months ended in the previous year 31/12/2015	Year to date figures for Current period ended 31/12/2016	Year to date figures for previous period ended 31/12/2015	Previous year ended 31/03/2016
PART-I							
1	Income From Operations						
a	Net Sales/ Income from Operations (Net of Excise duty)	5,154.32	5,006.78	7,724.90	14,962.01	25,289.13	32,063.07
b	Other Operating Income	59.67	13.23	121.52	162.44	385.78	559.10
	Total income from Operations (net):-	5,213.99	5,020.01	7,846.42	15,144.45	25,674.91	32,622.17
2	Expenditure						
a	Changes in inventories of finished goods, work-in-progress and stock-in-trade	297.80	(127.11)	(593.79)	287.17	(1,159.67)	(253.36)
b	Cost of Materials Consumed	3,485.79	3,754.95	6,656.12	10,845.39	20,659.98	24,892.62
c	Purchase of Stock -In-Trade	39.00	-	-	39.00	-	227.75
d	Employee Benefits Expense	168.67	152.86	170.08	483.12	498.07	657.74
e	Processing Charges	198.79	192.24	181.07	595.04	561.14	803.87
f	Power Fuel & Other Utility	75.78	72.67	107.42	220.26	299.74	347.68
g	Depreciation and amortisation expenses	51.49	41.65	62.99	144.49	168.36	225.88
h	Other Expenses	371.82	331.92	525.40	1,009.78	1,528.61	2,017.58
	Total Expenses :-	4,689.14	4,419.18	7,109.29	13,624.28	22,556.23	28,919.76
3	Profit From Operations before other income, Finance Costs & Exceptional Items	(1-2)	524.85	600.82	737.13	3,118.68	3,702.41
4	a Other Income	111.23	102.26	61.94	345.73	221.47	350.65
	b Exchange Gain/(Loss)	(60.84)	(6.31)	(26.53)	(63.45)	(242.04)	(255.11)
5	Profit from ordinary activities before finance costs & Exceptional Items	(3+4)	575.23	696.76	772.55	1,802.44	3,797.96
6	Finance Costs	0.35	0.77	1.03	1.43	1.26	4.25
7	Net Profit/(loss) for the period(before tax,Exceptional and/or Extra ordinary items	(5-6)	574.88	695.99	771.52	1,801.01	3,793.71
8	Exceptional Items	-	-	-	-	-	-
9	Net Profit/(loss) for the period(before tax after Exceptional and/or Extra ordinary items	(7+8)	574.88	695.99	771.52	1,801.01	3,793.71
10	Tax Expenses	150.00	209.00	250.00	500.00	1,030.00	1,213.28
11	Net Profit/(loss) for the period after tax (after Exceptional and/or Extra ordinary items)	(9-10)	424.88	486.99	521.52	1,301.01	2,580.43
12	Extraordinary Item (Net of Tax Expenses)	-	-	-	-	-	-
13	Total Comprehensive Income for the period (comprising profit for the period (after tax) and other comprehensive income (after tax)	424.88	486.99	521.52	1,301.01	2,066.86	2,580.43
14	Share of profit / (Loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit(+) / Loss(-) after taxes, minority interest and share of profit of profit / (loss) of associates	(13+14+15)	424.88	486.99	521.52	1,301.01	2,580.43
17	Paid up Equity Share Capital (Face value of Rs. 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80
18	Reserves excluding Revaluation Reserves as per Balance sheet of Previous Accounting Year						10,674.99
19	Earnings per Share(EPS) Face Value of Rs.5/-						
	Earnings Per Share(before and after Extraordinary items) (not annualised)						
	(a) Basic	1.70	1.94	2.08	5.19	8.25	10.30
	(b) Diluted	1.70	1.94	2.08	5.19	8.25	10.30

- The above Financial Results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their Meeting held on 13th February, 2017.
- The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".
- The above is an extract of the detailed format of Financial Results for the Quarter and Nine months ended on 31st December, 2016, filed with the Stock Exchange as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Nine months ended on 31st December, 2016 is available on the Stock Exchange website viz . www.bseindia.com and on the Company's website i.e. www.anuhpharma.com.
- Corresponding figures of the previous quarter have been regrouped, to make them comparable wherever necessary.

For and on behalf of Board of Directors
of Anuh Pharma Ltd.



Bharat N. Shah
Director
(DIN: 00083354)

Place : Mumbai
Date : 13th February, 2017

S. I. MOGUL & CO.
CHARTERED ACCOUNTANTS



73-B MITTAL COURT, NARIMAN POINT, MUMBAI 400021, INDIA

TEL : (91 22) 22842093, 22842159 | FAX : (91 22) 22822743 | E-MAIL : SIMCO@SIMOGUL.COM | WEBSITE : SIMOGUL.COM


LIMITED REVIEW REPORT

**TO THE BOARD OF DIRECTORS OF
ANUH PHARMA LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Anuh Pharma Limited ("Company")** for the quarter and nine months ended on December 31, 2016, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement ("**SRE**") 2410, '*Review of Interim Financial Information performed by the Independent Auditor of the Entity*' issued by the Institute of Chartered Accountants of India ("**ICAI**"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Mumbai, India: February 13, 2017

For S. I. MOGUL & CO.
Chartered Accountants
Firm Registration No. 106512W

Samir S. Mogul
Partner

Membership No. 100731